Frontiers in Cellular and Infection Microbiology (May 2024)

Molecular characterization of SARS-CoV-2 nucleocapsid protein

  • Yanping Huang,
  • Yanping Huang,
  • Junkai Chen,
  • Junkai Chen,
  • Siwei Chen,
  • Siwei Chen,
  • Congcong Huang,
  • Congcong Huang,
  • Bei Li,
  • Bei Li,
  • Bei Li,
  • Jian Li,
  • Jian Li,
  • Jian Li,
  • Zhixiong Jin,
  • Zhixiong Jin,
  • Zhixiong Jin,
  • Qiwei Zhang,
  • Pan Pan,
  • Weixing Du,
  • Long Liu,
  • Long Liu,
  • Long Liu,
  • Zhixin Liu,
  • Zhixin Liu,
  • Zhixin Liu

DOI
https://doi.org/10.3389/fcimb.2024.1415885
Journal volume & issue
Vol. 14

Abstract

Read online

Corona Virus Disease 2019 (COVID-19) is a highly prevalent and potent infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Until now, the world is still endeavoring to develop new ways to diagnose and treat COVID-19. At present, the clinical prevention and treatment of COVID-19 mainly targets the spike protein on the surface of SRAS-CoV-2. However, with the continuous emergence of SARS-CoV-2 Variants of concern (VOC), targeting the spike protein therapy shows a high degree of limitation. The Nucleocapsid Protein (N protein) of SARS-CoV-2 is highly conserved in virus evolution and is involved in the key process of viral infection and assembly. It is the most expressed viral structural protein after SARS-CoV-2 infection in humans and has high immunogenicity. Therefore, N protein as the key factor of virus infection and replication in basic research and clinical application has great potential research value. This article reviews the research progress on the structure and biological function of SARS-CoV-2 N protein, the diagnosis and drug research of targeting N protein, in order to promote researchers’ further understanding of SARS-CoV-2 N protein, and lay a theoretical foundation for the possible outbreak of new and sudden coronavirus infectious diseases in the future.

Keywords